Mobile

A phase 3 randomized, placebo-controlled, double-blind study of oral CCI-779 administered in combination with letrozole vs. letrozole alone as first line hormonal therapy in postmenopausal women with ...

Update Il y a 4 ans
Reference: EUCTR2004-000015-25

A phase 3 randomized, placebo-controlled, double-blind study of oral CCI-779 administered in combination with letrozole vs. letrozole alone as first line hormonal therapy in postmenopausal women with locally advanced or metastatic breast cancer

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Assessment of overall progression free survival (PFS)

Inclusion criteria

  • locally advanced or metastatic breast cancer (stage 3B or 4)

Links